IP Library Granted Patent US 7,662,914
Granted Patent B2
US 7,662,914 · App. 10/476,447 · Granted Feb 16, 2010

Native chemical ligation with three or more components

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,662,914
App. No.
10/476,447
Granted
Feb 16, 2010
Kind
B2
Abstract

The invention provides a method of assembling oligopeptide intermediates in a native chemical ligation reaction that eliminates self-ligation of bi-functional intermediates. An important aspect of the invention is a bi-functional intermediate with an N-terminal cyclic thiazolidine protecting group which effectively prevents self-ligation in the chemical assembly process. The present invention is useful in methods for convergent synthesis of polypeptides and proteins and improves the efficiency of native chemical ligation reactions, particularly where three or more peptide fragments are used to assemble a polypeptide or protein product.

Claims (19)

1. A method of synthesizing a polypeptide by ligation of three or more oligopeptide intermediates, the method comprising the steps of:

a) forming a ligation product between an oligopeptide possessing both an N-terminal thiazolidine protected cysteine and a C-terminal thioester, said oligopeptide having the formula:

wherein:

n is an integer from 2 to 100;

R 1 is selected from H, C 1-12 alkyl groups optionally substituted with 1-3 substituents selected from halo, nitro, amino, and amino oxycarbonylamino (H 2 N—O—CH 2 —CO—NH—);

R 2 is selected from H, C 1-12 alkyl groups optionally substituted with 1-3 substituents selected from halo, nitro, amino, and amino oxycarbonylamino (H 2 N—O—CH 2 —CO—NH—);

R 3 is H or an amino protecting group; and

R 4 is alkyl having from 1 to 6 carbon atoms or alkylaryl having from 6 to 8 carbon atoms,

—CH 2 —CONH 2 , —CH 2 CH 2 CONH 2 , or —(CH 2 ) k —CO—X aa , wherein k is an integer equal to 1 or 2 and Xaa is an amino acid,

and a second oligopeptide possessing an N-terminal cysteine;

b) treating the ligation product with a nucleophilic agent under acidic conditions to form a second ligation product having a free N-terminal cysteine; and

c) repeating steps a) and b) until the polypeptide is formed.

2. The method of claim 1 further including the step of purifying said prior ligation product prior to said step of forming.

3. The method of claim 2 wherein R 1 is selected from the group consisting of H, —CH 2 —NO 2 , —CH 2 Cl, —CH 2 Br, —CHCl 2 , —CHBr 2 .

4. The method of claim 3 wherein R 2 is selected from the group consisting of H, H 2 N—O—CH 2 —CO—NH—CH 2 —, H 2 N—O—CH 2 —CO—NH—CHCl—, and H 2 N—O—CH 2 —CO—NH—CHBr—.

5. The method of claim 3 or 4 wherein said nucleophilic agent is an O-alkylhydroxylamine of the formula H 2 N—O—R, where R is methyl, ethyl, isopropyl, isobutyl, or —CH 2 —COOH.

6. The method of claim 5 wherein said acidic conditions are in the range of pH 2.0 to pH 6.0.

7. The method of claim 6 wherein R 1 and R 2 are both hydrogen and wherein R 3 is Fmoc, Boc, or Nsc, whenever R 3 is said amino protecting group.

8. The method of claim 7 wherein said O-alkylhydroxylamine is O-methylhydroxylamine.

Assignments (4)
AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP Recorded Oct 26, 2012
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029195/0555 →
CHANGE OF NAME Recorded Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0340 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2007
From: GENEPROT, INC.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 018916/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2007
From: GENEPROT, INC.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 018916/0122 →